U.S. Markets close in 8 mins

Diffusion Pharmaceuticals Inc. (DFFN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.5229-0.0215 (-3.95%)
As of 3:52PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.5444
Open0.5400
Bid0.5226 x 1200
Ask0.5227 x 1100
Day's Range0.5100 - 0.5449
52 Week Range0.5100 - 1.8500
Volume960,583
Avg. Volume1,660,198
Market Cap53.286M
Beta (5Y Monthly)1.59
PE Ratio (TTM)N/A
EPS (TTM)-0.2760
Earnings DateAug 09, 2021 - Aug 13, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.00
  • Zacks Small Cap Research

    DFFN: TSC Causes Dose Dependent Increase in Tissue Oxygenation in TCOM Trial…

    By David Bautz, PhD NASDAQ:DFFN READ THE FULL DFFN RESEARCH REPORT Business Update Positive Trends Seen in TCOM Trial On June 30, 2021, Diffusion Pharmaceuticals, Inc. (NASDAQ:DFFN) announced topline results from the Phase 1 transcutaneous oxygen monitoring (TCOM) study of its lead development product trans sodium crocetinate (TSC). This study was designed to evaluate the exposure-reponse

  • Diffusion Pharma's TSC Shows Encouraging Effects On Oxygenation
    Benzinga

    Diffusion Pharma's TSC Shows Encouraging Effects On Oxygenation

    Diffusion Pharmaceuticals Inc (NASDAQ: DFFN) has announced topline results from the Phase 1 trial of its lead product candidate, trans sodium crocetinate (TSC). In the trial, transcutaneous oxygen monitoring (TCOM) was used to measure the direct pharmacodynamic effects of TSC on peripheral tissue oxygenation in healthy volunteers. Topline results were based upon analyses of primary endpoint data, which indicate, as compared to placebo, a positive dose-response trend in TCOM readings. Due to the

  • Diffusion Pharmaceuticals Reports Positive Trend in Oxygenation from TCOM Trial
    GlobeNewswire

    Diffusion Pharmaceuticals Reports Positive Trend in Oxygenation from TCOM Trial

    Trial Dosed Healthy Volunteers with Trans Sodium CrocetinateCHARLOTTESVILLE, Va., June 30, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced topline results from the Company’s Phase 1 trial of its lead product candidate, trans sodium crocetinate (“TSC”). In this trial, transcutan